Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Corvus Pharmaceuticals In...

    NASDAQ: CRVS · Real-Time Price · USD
    3.48
    0.28 (8.75%)
    At close: May 08, 2025, 12:36 PM
    8.75%
    Bid 3.42
    Market Cap 237.11M
    Revenue (ttm) n/a
    Net Income (ttm) -62.29M
    EPS (ttm) -1.02
    PE Ratio (ttm) -3.41
    Forward PE -18.5
    Analyst Buy
    Ask 3.52
    Volume 396,683
    Avg. Volume (20D) 760,150
    Open 3.20
    Previous Close 3.20
    Day's Range 3.16 - 3.48
    52-Week Range 1.75 - 10.00
    Beta 0.66

    About CRVS

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol CRVS
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for CRVS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    -14.76%
    Corvus Pharmaceuticals shares are trading lower af... Unlock content with Pro Subscription
    4 months ago
    -36.4%
    Corvus Pharmaceuticals shares are trading lower. The company announced interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.
    news image

    1 month ago · seekingalpha.com

    Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials

    Corvus Pharmaceuticals' leading drug candidate is Soquelitinib, which has broad potential across PTCL, atopic dermatitis, and ALPS. Unfortunately, it seems Corvus' early AD data might have disappointe...

    news image

    1 month ago · seekingalpha.com

    Corvus Pharmaceuticals: Now At Cruising Altitude

    Corvus Pharmaceuticals' stock has experienced volatility due to mixed clinical data, particularly from their lead asset soquelitinib's Phase 1 trial in atopic dermatitis. The company has promising dev...

    news image

    1 month ago · seekingalpha.com

    Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript

    Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q4 2024 Earnings Conference Call March 25, 2025 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Leiv Lea - CFO Richard Miller - CEO Conferen...

    Add to Watchlist